Skip to main content
Journal cover image

Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.

Publication ,  Journal Article
Patel, A; Ravaud, A; Motzer, RJ; Pantuck, AJ; Staehler, M; Escudier, B; Martini, J-F; Lechuga, M; Lin, X; George, DJ
Published in: Future Oncol
February 2021

Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). Results: In 609 patients, DFS was similar for baseline PLR <140 versus ≥140 overall (median: 6.4 vs 5.9 years; hazard ratio: 0.9; 95% CI: 0.7-1.2). A ≥25% decrease in PLR at week 4 overall was associated with longer DFS versus no change (hazard ratio: 0.8; 95% CI: 0.6-1.0). Conclusion: Baseline PLR was not prognostic for DFS with adjuvant sunitinib treatment in patients with renal cell carcinoma. Clinical Trials Registration: NCT00375674 (ClinicalTrials.gov).

Duke Scholars

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

February 2021

Volume

17

Issue

4

Start / End Page

403 / 409

Location

England

Related Subject Headings

  • Young Adult
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lymphocytes
  • Kidney Neoplasms
  • Humans
  • Female
  • Disease-Free Survival
  • Carcinoma, Renal Cell
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, A., Ravaud, A., Motzer, R. J., Pantuck, A. J., Staehler, M., Escudier, B., … George, D. J. (2021). Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncol, 17(4), 403–409. https://doi.org/10.2217/fon-2020-0652
Patel, Anup, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, and Daniel J. George. “Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.Future Oncol 17, no. 4 (February 2021): 403–9. https://doi.org/10.2217/fon-2020-0652.
Patel A, Ravaud A, Motzer RJ, Pantuck AJ, Staehler M, Escudier B, et al. Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncol. 2021 Feb;17(4):403–9.
Patel, Anup, et al. “Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.Future Oncol, vol. 17, no. 4, Feb. 2021, pp. 403–09. Pubmed, doi:10.2217/fon-2020-0652.
Patel A, Ravaud A, Motzer RJ, Pantuck AJ, Staehler M, Escudier B, Martini J-F, Lechuga M, Lin X, George DJ. Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncol. 2021 Feb;17(4):403–409.
Journal cover image

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

February 2021

Volume

17

Issue

4

Start / End Page

403 / 409

Location

England

Related Subject Headings

  • Young Adult
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lymphocytes
  • Kidney Neoplasms
  • Humans
  • Female
  • Disease-Free Survival
  • Carcinoma, Renal Cell